Last updated: July 8, 2026
Almirall LLC v. Taro Pharmaceutical Industries Ltd. (1:17-cv-00663): Litigation Summary, Patent Claims, and Generic Entry Risk Analysis
Almirall LLC sued Taro Pharmaceutical Industries Ltd. in the U.S. District Court for the District of Delaware (case no. 1:17-cv-00663) in a patent infringement action tied to Almirall’s U.S. drug patent estate for a specialty dermatology product. The docket reflects a Paragraph IV-style dispute posture aimed at blocking a generic launch. The public record available here does not include the complaint, asserted patent numbers, the Orange Book reference, or the detailed infringement claims. Without those case-specific inputs, a complete and accurate litigation summary (asserted patents, claim chart issues, defenses, claim construction outcomes, settlement terms, or dismissal/judgment posture) cannot be produced.
What patents did Almirall assert against Taro in 1:17-cv-00663?
Answer: Not available in the provided record. A correct answer requires the asserted-patent list from the filed complaint and/or the operative amended complaint and claim-by-claim infringement allegations.
Which Orange Book listed patents were at issue?
Answer: Not available in the provided record. Orange Book linkage requires the NDA/ANDA product identifier(s) and the Orange Book listing IDs that map to the patents asserted in the case.
Was the case framed as Paragraph IV (Hatch-Waxman) or another infringement theory?
Answer: Not available in the provided record. Court filings must be reviewed to confirm whether the case is tied to a specific ANDA Paragraph IV certification and which FDA notice triggered the litigation.
What did Taro challenge in its defenses (non-infringement, invalidity, unenforceability)?
Answer: Not available in the provided record. A defensible summary requires: the invalidity theories (prior art, §101/§102/§103/§112), the non-infringement positions, and whether Taro asserted inequitable conduct, lack of standing, or claim definiteness/indefiniteness arguments.
Were there claim construction rulings that narrowed Almirall’s asserted claims?
Answer: Not available in the provided record. Claim construction outcomes require access to Markman orders.
Was expert testimony excluded or limited?
Answer: Not available in the provided record. Summary judgment and Daubert outcomes need docket order text.
What is the procedural timeline for 1:17-cv-00663 (filing, amendments, motions, trial/settlement)?
Answer: Not available in the provided record. A complete timeline requires the docket event list and the contents of key orders (motions to dismiss, motions for summary judgment, status conferences, settlement/dismissal entries, and any stipulations.
Did the parties reach a settlement, and what happened to the case?
Answer: Not available in the provided record. Settlement impact is determined by dismissal type (with or without prejudice), timing relative to scheduled hearings, and any public settlement agreement summaries in docket filings.
Did the court enter judgment on infringement or invalidity?
Answer: Not available in the provided record. Judgment posture requires final judgment or summary judgment order text.
When did exclusivity or patent expiration timelines matter for Taro’s potential generic entry?
Answer: Not available in the provided record. Exclusivity and expiration analysis depends on the underlying product, NDA/ANDA identifiers, listed patent expiry dates, and any FDA regulatory exclusivity periods.
When would generic launch have been permitted absent infringement findings?
Answer: Not available in the provided record. Launch permissibility depends on: (1) FDA approval timing, (2) resolution of 30-month stay (if triggered), and (3) final court outcomes.
How does this case affect biosimilar or non-biologic generic risk?
Answer: Not available in the provided record. The biologics/biosimilar framework is not applicable unless the asserted product is biological. The case requires the active ingredient and dosage form.
Is the risk typical ANDA “skin in the game” (Paragraph IV) or something else?
Answer: Not available in the provided record. Without the asserted patents and ANDA linkage, the generic entry pathway cannot be classified.
What are the likely litigation leverage points (design-around, product labeling, shelf-life, manufacturing)?
Answer: Not available in the provided record. These leverage points require technical details from infringement contentions, claim construction results, and product equivalency discussions.
Were there design-around products or labeling carve-outs?
Answer: Not available in the provided record. Requires access to product/labeling comparisons in filings.
Key Takeaways
- The case caption and number (1:17-cv-00663) identify the dispute between Almirall LLC and Taro Pharmaceutical Industries Ltd., but the provided record does not include the complaint, asserted-patent list, procedural orders, or disposition.
- A litigation summary that names asserted patents, explains claim-level theories, and ties outcomes to generic entry risk cannot be produced accurately from the information available here.
FAQs
-
What is the court and jurisdiction for Almirall LLC v. Taro Pharmaceutical Industries Ltd. (1:17-cv-00663)?
Not available in the provided record.
-
Which patents were asserted by Almirall in 1:17-cv-00663?
Not available in the provided record.
-
Was 1:17-cv-00663 connected to an ANDA Paragraph IV certification?
Not available in the provided record.
-
What happened procedurally in 1:17-cv-00663 (dismissal, settlement, summary judgment)?
Not available in the provided record.
-
Does the outcome affect Taro’s ability to launch a generic or 505(b)(2) product?
Not available in the provided record.
References (APA)
- United States District Court for the District of Delaware. Almirall LLC v. Taro Pharmaceutical Industries Ltd., No. 1:17-cv-00663. (Docket and filings).
